Byetta Lawsuits: Pancreatitis, Pancreatic Cancer
Commonly asked questions about Byetta (exenatide):
- What is it?
- What are serious side effects?
- What are the less serious side effects?
- What claims have been filed against it?
- Can I file a lawsuit?
- How do I start a claim?
What Is Byetta?
Byetta (exenatide) is an injectable twice daily drug used to treat type 2 diabetes. It was approved by the U.S. Food and Drug Administration in 2005, and has been prescribed by physicians to millions of Americans in the last decade.
It is a glucagon like peptide-1 receptor agonist, or GLP-1. It falls into the same class of drug as Victoza, another diabetes drug currently facing litigation. Byetta is used in combination with proper diet and exercise to control blood sugar levels in patients with type 2 diabetes. In January 2012, the FDA also approved Bydureon, a version that is only to be taken once daily.
What Are Serious Side Effects Of Byetta?
Although it is used by millions of people who suffer from type 2 diabetes, there is growing concern about a number of complications believed to be linked to the GLP-1 class of drugs. Pancreatitis, a condition that occurs when enzymes inside the body begin attacking the pancreas, is one of these complications. If not treated, pancreatitis can worsen and sometimes even be fatal. Addtionally, if left untreated or ignored, pancreatitis can lead to pancreatic cancer.
Pancreatic cancer is a second serious complication associated with GLP-1 drugs. Cancer in the pancreas is extremely dangerous because there are rarely symptoms present until much later in its development, causing patients to be misdiagnosed, or not diagnosed in a timely manner. Pancreatic cancer is a life-threatening disease that is treatable, but the sooner it is discovered, the better chance of survival the patient has.
What Are The Less Serious Side Effects Of Byetta?
RxList lists the less serious side effects. These side effects include one or more of the following:
- Upset Stomach
- Weight loss
- Loss of appetite
TV Commercial About Byetta Lawsuits
What Claims Have Been Filed Against Byetta?
There have been many lawsuits filed since the drug’s initial release in 2005, some of the lawsuits reported by Drug Watch include:
The estate of Regina Kelly filed a suit against Mark, Amylin and Eli Lilly. She had developed pancreatic cancer after taking the prescription drugs Januvia and Byetta. Her estate alleges that the drugs “permanently and severely injured” her, ultimately being the cause of her death.
Joel Whiteley’s mother, was prescribed Januvia in August of 2007. She died of pancreatic cancer in August 2009. Her son was able to file personal injury claims on behalf of her estate as well as a wrongful death claim. The case is currently pending in the federal MDL, and discovery in currently underway.
Can I File A Byetta Lawsuit?
Our dangerous drug attorneys can help if you or someone you care about was harmed. Lawsuits have been filed against Bristol-Myers Squibb, the drug maker, by both patients and their families seeking compensation for injuries caused by this dangerous drug. You may be entitled to a settlement. We do not charge any legal fees unless you receive a settlement and we pay all of the case costs. If your claim is not successful for any reason, you do not owe us anything. We put it all in writing for you.
Our No-Fee Promise on Byetta Cases
You can afford to have our great team of lawyers on your side. When you choose us, it literally costs nothing to get started. We promise you in writing:
- No money to get started
- We pay all case costs and expenses
- No legal fees whatsoever unless you receive a settlement
- Phone calls are always free
How Do I Start A Byetta Claim?
Our lawyers will help you file your lawsuit. To get started, you can:
- Submit the Free Case Review Box on this page, or
- Call (866) 280-4722 any time of day to tell us about your case.
We will listen to your story and answer your questions. If you have claim, we will start immediately.
WARNING: There are strict time deadlines for filing lawsuit claims.